After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.

Gilead is the latest drugmaker to announce that it’s pouring billions of dollars into its manufacturing and R&D operations in ...

CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...

Federal appeals court overturns order blocking Avadel Pharmaceuticals from seeking FDA approval for Lumryz in idiopathic ...

NewAmsterdam's obicetrapib reduced Lp(a) by 45% in Phase 3; C4 Therapeutics advances cemsidomide while dropping CFT1946; Vivo ...

Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...

Theriva Biologics' VCN-01 plus chemotherapy showed improved survival in pancreatic cancer patients vs. chemo alone in Phase ...

Los Angeles-based health system Cedars-Sinai is partnering with venture studio Redesign Health to build health tech startups ...